[1] [1] RABE K F, WATZ H. Chronic obstructive pulmonary disease［J］. Lancet, 2017, 389(10082): 1931-1940.

[2] [2] WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health［CPH］ study): a national cross-sectional study［J］. Lanect, 2018, 391(10131): 1706-1717.

[3] [3] SUN Y, SIN D D. Crisis of COPD in China: the future is now［J］. The Lancet Respiratory Medicine, 2018, 6(6): 404-405.

[4] [4] FANG L, GAO P, BAO H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study［J］. The Lancet Respiratory Medicine, 2018, 6(6): 421-430.

[7] [7] DECRAMER M, JANSSENS W, MIRAVITLLES M. Chronic obstructive pulmonary disease［J］. Lancet, 2012, 379(9823): 1341-1351.

[8] [8] RITCHIE A I, WEDZICHA J A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations［J］. Clinics in Chest Medicine, 2020, 41(3): 421-438.

[9] [9] MAMMEN M J, SETHI S. COPD and the microbiome［J］. Respirology, 2016, 21(4): 590-599.

[10] [10] ARMITAGE M N, SPITTLE D A, TURNER A M. A systematic review and meta-analysis of the prevalence and impact of pulmonary bacterial colonisation in stable state chronic obstructive pulmonary disease (COPD)［J］. Biomedicines, 2021, 10(1): 81.

[11] [11] SZE M A, HOGG J C, SIN D D. Bacterial microbiome of lungs in COPD［J］. International Journal of Chronic Obstructive Pulmonary Disease, 2014, 9: 229-238.

[16] [16] D’ANNA S E, MANISCALCO M, CAPPELLO F, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease［J］. Annals of Medicine, 2021, 53(1): 135-150.

[17] [17] WILSON R, SETHI S, ANZUETO A, et al. Antibiotics for treatment and prevention of?exacerbations of chronic obstructive pulmonary disease［J］. The Journal of Infection, 2013, 67(6): 497-515.

[18] [18] LEE C R, LEE J H, PARK M, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options［J］. Frontiers in Cellular and Infection Microbiology, 2017, 7: 55.

[19] [19] IBRAHIM S, AL-SARYI N, AL-KADMY I, et al. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals［J］. Molecular Biology Reports, 2021, 48(10): 6987-6998.

[20] [20] GARNACHO-MONTERO J, TIMSIT J F. Managing Acinetobacter baumannii infections［J］. Current Opinion in Infectious Diseases, 2019, 32(1): 69-76.

[21] [21] PANG Z, RAUDONIS R, GLICK B R, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies［J］. Biotechnology Advances, 2019, 37(1): 177-192.

[22] [22] GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990―2017: a systematic analysis for the Global Burden of Disease Study 2017［J］. The Lancet Respiratory Medicine, 2020, 8(6): 585-596.